Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease

Published:2014-02 Issue:2 Volume:20 Page:339-352
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

de Bruyn Magali,Machiels Kathleen,Vandooren Jennifer,Lemmens Bart,Van Lommel Leentje,Breynaert Christine,Van der Goten Jan,Staelens Dominiek,Billiet Thomas,De Hertogh Gert,Ferrante Marc,Van Assche Gert,Vermeire Séverine,Opdenakker Ghislain,Schuit Frans,Rutgeerts Paul,Arijs Ingrid

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference39 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease

2. Mucosal expression of matrix metalloproteinases and their tissue inhibitors in ulcerative colitis patients

3. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

4. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Matrix metalloproteinase-responsive hydrogels with tunable retention for on-demand therapy of inflammatory bowel disease;Acta Biomaterialia;2024-09

2. Matrix metalloproteinases in intestinal fibrosis;Journal of Crohn's and Colitis;2023-10-25

3. Identification of mRNA Signature for Predicting Prognosis Risk of Rectal Adenocarcinoma;Frontiers in Genetics;2022-05-18

4. Metalloendopeptidase ADAM-like Decysin 1 (ADAMDEC1) in Colonic Subepithelial PDGFRα+ Cells Is a New Marker for Inflammatory Bowel Disease;International Journal of Molecular Sciences;2022-04-30

5. Topical phenytoin administration accelerates the healing of acetic acid-induced colitis in rats: evaluation of transforming growth factor-beta, platelet-derived growth factor, and vascular endothelial growth factor;Inflammopharmacology;2022-01-13